title: Clofazimine, Psora-4 and PAP-1, inhibitors of the potassium channel Kv1.3, as a new and selective therapeutic strategy in chronic lymphocytic leukemia.
authors: L
authors: L
authors: Leanza
authors: L
authors: L
authors: Trentin
authors: K A
authors: KA
authors: Becker
authors: F
authors: F
authors: Frezzato
authors: M
authors: M
authors: Zoratti
authors: G
authors: G
authors: Semenzato
authors: E
authors: E
authors: Gulbins
authors: I
authors: I
authors: Szabo
mesh_terms: D002991:Clofazimine / Q000494:pharmacology / Q000627:therapeutic use*; D005363:Ficusin / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D051664:Kv1.3 Potassium Channel / Q000037:antagonists & inhibitors*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000378:metabolism; D000073718:Pancreatitis-Associated Proteins; D026902:Potassium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: C499898:5-(4-phenylbutoxy)psoralen; D051664:Kv1.3 Potassium Channel; D000073718:Pancreatitis-Associated Proteins; D026902:Potassium Channel Blockers; C000612141:REG3A protein, human; D002991:Clofazimine; D005363:Ficusin